Tag Archives: Bausch & Lomb

Valeant CEO tries to paint happy face on 4Q results; markets not buying the turnaround–yet?

The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Valeant stock plunges anew on dismal 3Q results; behold another pharma Sisyphus

After an already noisy year, Valeant Pharmaceuticals International Inc. (Laval Québec) once again took investors off guard–this time, on Election Day–as new management cut the annual profit forecast to well… Read more »

Needing cash, Valeant in talks to sell stomach-drug unit in $10 billion deal; hedge-fund icon Bill Ackman finally has a good day

Valeant Pharmaceuticals International Inc. (Laval Quebec) is in advanced talks to sell a big stomach-drug business to Japan’s Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its… Read more »

Valeant Plummets on Criminal Probe of Philidor Unit

Valeant Pharmaceuticals International Inc. (Laval Quebec) did an about-face and fell 11% on Thursday as new details about a criminal investigation into the drugmaker reignited investor concerns about the company’s… Read more »